Key investor takeaways:
- Product development: Quantum-Si reports a major technical milestone for its next-generation Proteus platform—successful fully integrated sequencing runs with developmental reagents and arrays. Proteus currently detects 17 amino acids (up from 15 in Dec 2025); company targets 18 by commercial delivery in 2026, demonstration of all 20 amino acids during 2026, and a full 20-amino-acid sequencing kit in 2027. Management characterizes Proteus as materially superior to Platinum on throughput, automation, signal-to-noise, amino-acid detection frequency, and average read length.
- Post-translational modification (PTM) capability: Quantum-Si is prioritizing PTM detection via kinetic signatures and AI-enabled analysis (rather than affinity-based approaches), positioning Proteus to offer site-resolved PTM detection with a universal sequencing chemistry.
- Commercial preparation: The company is running a Proteus roadshow program to educate users, build demand, and develop a funnel of potential customers. Early feedback and a first customer sample run on Proteus were positive (higher amino-acid detection and ~2x read length vs Platinum). Plan includes offering sample evaluations and a handful of early access sites across academic and commercial segments over the summer/fall.
- Manufacturing & launch execution: Near-term work focuses on systems integration, reliability, manufacturing transfer and building an internal R&D fleet to support development and early access. Broader inventory buildup for sales is expected later in the year, paced to funnel/preorder signals.
- Financials and runway: Q1 revenue was $0.258M; gross profit $0.074M (29% margin). GAAP operating expenses $24.1M (adj OpEx $21.4M). Cash, cash equivalents and marketable securities were $190.4M at 3/31/2026. 2026 outlook: total revenue ~ $1M, adjusted operating expenses ≤ $98M, and total cash usage ≤ $93M. Management expects cash to support operations into 2028 (roughly 1.5 years after estimated Proteus launch) and plans to reduce R&D spend post-launch by leveraging external partners to extend runway.
- Capital-sales posture: 2026 treated as a transition year—few new capital sales expected as customers time purchases for Proteus. Some Platinum Pro sales include embedded upgrade credits toward Proteus (optional for customers), which can depress near-term revenue but preserve customer goodwill toward upgrading.
- Governance/insider alignment: Management retains meaningful insider ownership; two board members purchased 600k shares in the quarter. Recent insider Form 4 activity was routine (tax-related), no opportunistic selling disclosed.
Overall investment implications: the transcript signals meaningful technical de-risking for Proteus and early customer validation, while the company maintains financial discipline and a multi-year cash runway. Key near-term value drivers are successful execution of manufacturing/commercial launch, expansion of PTM capabilities, conversion of early evaluations into instrument purchases, and demonstration of unit economics (consumable pull-through) post-launch.
Sign In
Buy QSIAW
